Numerous studies have also established the MDM2 gene’s efficacy as a prognostic biomarker in a variety of cancer types, including human lung carcinomas, cervical carcinogenesis, bladder cancer, neck cancer, and ovarian cancer, as well as glioblastoma [50,51]. Here, MDM2 is linked to ovarian carcinoma.